Home Drug Codes J Codes J2425 · KEPIVANCE
Updated July 1st, 2026

KEPIVANCE J Code: J2425

Injection, palifermin, 50 micrograms

Login to unlock all benchmarks

Q4 2026 Medicare Payment Limit for J2425, effective October 1, 2026: $38.839 per HCPCS billing unit, up 0.4% from $38.69. From CMS's final file.

?
Medicare Payment Limit ?
$38.69
/ HCPCS billing unit · Q3 2026
APC Payment Limit ?
$38.69
/ HCPCS billing unit · APC 1696
ASP ?
$•••.••
Login to view
WAC · AWP ?
$•••.••
Login to view
NDCs Crosswalked ?
3
View NDC crosswalk →

Drug & Product Overview

HCPCS Descriptor Injection, palifermin, 50 micrograms
HCPCS Added Date January 1, 2006
Manufacturer Sobi
Route of Administration Intravenous
Generic Status Single-Source; Branded
Dosage Type Single-Dose
Dosage Form Injection, Powder, Lyophilized, For Solution

About KEPIVANCE

Kepivance is a medication aligned to the HCPCS J Code: J2425 for billing, pricing, and reimbursement purposes in the United States. It is an Oncology drug administered via the intravenous route and manufactured by Sobi.

According to CMS Drug Use Information: Palifermin is used by people with blood or bone marrow cancer (such as leukemia, multiple myeloma) who are receiving chemotherapy or radiation along with stem cell transplant. The chemotherapy or radiation can cause severe sores in the mouth and throat (mucositis). Palifermin is used to decrease the risk of these sores and to decrease the time it takes for these sores to heal. Palifermin may work by increasing the growth of cells in the mouth and throat. This medication should only be used by patients with blood or bone marrow cancer, and not by patients with other types of cancer.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. Showing 2 of 3 NDCs — log in for the full crosswalk.

NDC Code Drug Manufacturer Billing Units / Pkg Package Size
66658-0113-03 Kepivance Swedish Orphan Biovitrum AB (publ) 310 5160 MCG / 1.2 ML
66658-0113-06 Kepivance Swedish Orphan Biovitrum AB (PuBL) 620 5.16 MG
•••••-••••-•• Log in to view KEPIVANCE
Login to view 1 more NDC package View pricing, complete NDC-to-HCPCS alignments, and package details.
Login →

KEPIVANCE Pricing & Reimbursement

J2425 Private Payer Reimbursement
$36.47 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →
UnitedHealthcare, BlueCross BlueShield, Aetna, Cigna

Historical Graphing and Billing Calculator

per HCPCS unit
As of Q3 2026

KEPIVANCE CPT Administration Codes

The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.

CPT Code Description
96413 Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415 Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)
JW / JZ modifiers apply

CMS has identified Kepivance (J2425) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

KEPIVANCE Medically Unlikely Edits (MUE)

The most billing units of J2425 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 50 mcg.

Practitioner Office & Hospital Outpatient
125 units / day
= 6,250 mcg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

mcg Enter a dose to see how many billing units it is and whether it is under the limit.

KEPIVANCE Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

severe oral mucositis in hematologic malignancies receiving myelotoxic therapy with autologous hematopoietic stem cell support
Drug Class
Fibroblast Growth Factor 7 [CS]Increased Epithelial Proliferation [PE]Mucocutaneous Epithelial Cell Growth Factor [EPC]

Login for BuyandBill.com Analytics

Unlock deeper insights with BuyandBill’s Comparative Report!

  • Compare ASP, WAC, and AWP across drugs.
  • Visualize Drug Price Movement Over Time
  • Tailor reports to drug class, manufacturer, or HCPCS Code.
  • Compare Biosimilar and 505(b)(2) products.

Frequently Asked Questions

Is there an available Kepivance billing and coding guide?
We have not yet identified a manufacturer source of Kepivance billing and coding information.
Are there any available Kepivance patient assistance programs?
Our team did not identify a source for Kepivance patient assistance information. Please reach out to our team if you feel that this is a mistake.
Where can I find Kepivance prescribing information?
KEPIVANCE prescribing information can be found at the link below: Visit Here →
Where can I find Kepivance side effect information?
Information regarding KEPIVANCE's side effects can be found at MedlinePlus Visit Here →
Does billing KEPIVANCE require JZ/JW wastage modifiers?
CMS has identified KEPIVANCE(J2425) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.